Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Laura L. Meijer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5909-9314; OpenAlex author ID A5030102466. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers

Papers 17

  1. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  2. In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations. Co-author DOI 10.1111/cas.16147↗
  3. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  4. Spatial immune composition of tumor microenvironment in patients with pancreatic cancer. Co-author DOI 10.1007/s00262-023-03573-6↗
  5. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-05219-7↗
  6. hENT1 as a Predictive Biomarker in PDAC-Letter. Co-author DOI 10.1158/1078-0432.ccr-22-3827↗
  7. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Co-author DOI 10.1038/s42003-021-02934-0↗
  8. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel A… Co-author DOI 10.3390/cancers14020344↗
  9. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003084↗
  10. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. Co-author DOI 10.1172/jci.insight.138290↗
  11. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. First author DOI 10.1634/theoncologist.2019-0680↗
  12. Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, …but do they contradict themselves? Co-author DOI 10.1016/j.critrevonc.2019.102824↗
  13. The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of g… Co-author DOI 10.1080/14737159.2018.1544495↗
  14. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Co-author DOI 10.1080/14737159.2016.1175940↗
  15. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. First author DOI 10.3748/wjg.v22.i31.6987↗
  16. Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. Co-author DOI 10.1038/ajg.2015.77↗
  17. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. First author DOI 10.1586/14737159.2015.1112273↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Kazemier M · 17 shared papers, 2015–2024 · strength 2.01
  2. Elisa Giovannetti · 15 shared papers, 2015–2024 · strength 1.68
  3. Tessa Y. S. Le Large · 13 shared papers, 2015–2024 · strength 1.49
  4. Lenka N.C. Boyd · 7 shared papers, 2020–2024 · strength 1.10
  5. Hanneke W.M. van Laarhoven · 6 shared papers, 2020–2024 · strength 0.84
  6. Eline S. Zwart · 5 shared papers, 2019–2024 · strength 0.76
  7. Jisce R. Puik · 4 shared papers, 2022–2024 · strength 0.65
  8. Yvette van Kooyk · 4 shared papers, 2022–2024 · strength 0.63
  9. Adam Enver Frampton · 6 shared papers, 2015–2024 · strength 0.62
  10. Ingrid Garajová · 4 shared papers, 2016–2024 · strength 0.49
  11. Marc G. Besselink · 3 shared papers, 2023–2024 · strength 0.49
  12. Ernesto Rodríguez · 3 shared papers, 2022–2024 · strength 0.47
  13. Maarten F. Bijlsma · 4 shared papers, 2016–2022 · strength 0.36
  14. Johanna W. Wilmink · 2 shared papers, 2023–2024 · strength 0.34
  15. Annalisa Comandatore · 2 shared papers, 2023–2024 · strength 0.32
  16. Luca Morelli · 2 shared papers, 2023–2024 · strength 0.32
  17. Niccola Funel · 3 shared papers, 2016–2020 · strength 0.27
  18. Freek D. Daams · 2 shared papers, 2020–2022 · strength 0.23
  19. Babs M. Zonderhuis · 2 shared papers, 2020–2022 · strength 0.23
  20. Dongmei Deng · 2 shared papers, 2018–2019 · strength 0.19
  21. Connie R. Jiménez · 2 shared papers, 2020 · strength 0.19
  22. Chiara Caparello · 2 shared papers, 2016–2020 · strength 0.17
  23. Enrico Vasile · 2 shared papers, 2016–2020 · strength 0.17
  24. Andrea Mambrini · 1 shared paper, 2024 · strength 0.17
  25. Rutger‐Jan Swijnenburg · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.